中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.009 seconds)

    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN
    1.
    发明申请
    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
    持续发行包含孕激素的药物组合物

    公开(公告)号：WO2012035559A2

    公开(公告)日：2012-03-22

    申请号：PCT/IN2011/000638

    申请日：2011-09-15

    Applicant: PANACEA BIOTEC LTD ,  JAIN, Rajesh ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    Inventor： JAIN, Rajesh ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    IPC: A61K9/52

    CPC classification number: A61K9/0002 ,  A61K9/1623 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/197 ,  A61K47/26

    Abstract: The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.

    Abstract translation: 本发明涉及稳定的每日一次的持续释放药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普通巴布林常规立即释放制剂每天两次生物等效。 本发明还涉及包含普瑞巴林和糖酯作为释放阻滞剂的组合物，其用于保持药物的均匀释放速率和用于制备这种口服持续释放制剂的方法。

    MODIFIED DOSAGE FORMS OF TACROLIMUS
    2.
    发明申请
    MODIFIED DOSAGE FORMS OF TACROLIMUS 审中-公开
    改良剂量剂型

    公开(公告)号：WO2009022354A3

    公开(公告)日：2009-04-09

    申请号：PCT/IN2008000179

    申请日：2008-03-25

    Applicant: PANACEA BIOTEC LTD ,  SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND ,  JAIN RAJESH

    Inventor： SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND ,  JAIN RAJESH

    IPC: A61K31/4745 ,  A61K9/22

    CPC classification number: A61K9/146 ,  A61K9/1676 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/436

    Abstract: The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.

    Abstract translation: 本发明提供了他克莫司的释放剂型，其口服给药释放两种或更多量的他克莫司，第一批量的他克莫司基本上立即在0-2小时内立即从立即释放剂量单位释放，之后是从约 1-10小时，其中基本上没有量的他克莫司从剂型中释放出来，之后第二量的他克莫司被释放，其中所述第二量从延迟释放剂量单位释放， 在0-2小时内或超过延迟释放剂量单位从其初始释放约2-12小时的时间段内。 剂型还可包含额外量的他克莫司以提供他克莫司的额外脉冲。 他克莫司的剂型表现出改善的生物利用度和减少通量或波动超过现有组合的他克莫司。 还描述了制备剂型的方法。

    PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY
    4.
    发明申请
    PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY 审中-公开
    可编程交付技术

    公开(公告)号：WO2008062440A3

    公开(公告)日：2008-07-31

    申请号：PCT/IN2007000392

    申请日：2007-09-03

    Applicant: PANACEA BIOTEC LTD ,  SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND ,  TANDALE RAJENDRA

    Inventor： SINGH AMARJIT ,  SINGH SARABJIT ,  PUTHLI SHIVANAND ,  TANDALE RAJENDRA

    IPC: A61K9/24 ,  A61K47/30

    CPC classification number: A61K9/0065 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/2886

    Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

    Abstract translation: 本发明涉及用于活性剂的空间和时间可编程递送的系统。 口服给药时，可以将系统长时间保留在胃区。 它包括芯（I），涂覆在芯上的一层或多层（II，IV，V）和预成型的中空空间（III）。 本发明还涉及通过向有需要的受试者施用本发明的系统来制备该系统的方法和一种治疗/预防疾病的方法。

    PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF
    5.
    发明申请
    PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF 审中-公开
    用于递送活性成分的颗粒，其制备方法和组合物

    公开(公告)号：WO2008062429A3

    公开(公告)日：2008-11-13

    申请号：PCT/IN2007000340

    申请日：2007-08-10

    Applicant: PANACEA BIOTEC LTD ,  SINGH AMARJIT ,  SINGH SARABJIT ,  SINGH PARAMJIT ,  JAIN RAJESH

    Inventor： SINGH AMARJIT ,  SINGH SARABJIT ,  SINGH PARAMJIT ,  JAIN RAJESH

    IPC: B82B3/00 ,  A61K9/00 ,  A61K9/51 ,  A61K47/30

    CPC classification number: A61K9/19 ,  A61K9/5115 ,  A61K9/5161 ,  A61K9/5192 ,  B82Y5/00

    Abstract: The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.

    Abstract translation: 本发明公开了具有包含无机元素的颗粒的组合物; 一种或多种活性成分和任选的释放速度调节剂，其适用于将活性成分递送至人和动物组织。 颗粒是纳米颗粒或微颗粒或其混合物，优选通过溶胶 - 凝胶方法制备。 该组合物可用于局部或粘膜表面，优选以霜剂，凝胶剂，洗剂，干粉剂，喷雾剂，泡沫剂和其它合适的形式施用。

    POST-OCR IMAGE SEGMENTATION INTO SPATIALLY SEPARATED TEXT ZONES
    6.
    发明申请
    POST-OCR IMAGE SEGMENTATION INTO SPATIALLY SEPARATED TEXT ZONES 审中-公开
    将OCR后图像分割为空间分离的文本区域

    公开(公告)号：WO2007022460A3

    公开(公告)日：2007-12-13

    申请号：PCT/US2006032483

    申请日：2006-08-18

    Applicant: DIGITAL BUSINESS PROCESSES INC ,  ROMANOFF HARRIS ,  SPERO LESLIE ,  SINGH SARABJIT

    Inventor： ROMANOFF HARRIS ,  SPERO LESLIE ,  SINGH SARABJIT

    IPC: G06K9/00 ,  G06K9/18 ,  G06K9/48

    CPC classification number: G06K9/00463

    Abstract: This invention describes a post-recognition procedure to group text recognized by an Optical Character Reader (OCR) from a document image into zones. Once the recognized text and the corresponding word bounding boxes for each word of the text are received, the procedure described dilates (expands) these word bounding boxes by a factor and records those which cross. Two word bounding boxes will cross upon dilation if the corresponding words are very close to each other on the original document. The text is then grouped into zones using the rule that two words will belong to the same zone if their word bounding boxes cross upon dilation. The text zones thus identified are sorted and returned.

    Abstract translation: 本发明描述了一种识别后期过程，以将由光学字符读取器（OCR）识别的文本从文档图像分组为区域。 一旦接收到文本的每个单词的识别的文本和相应的单词边界框，所描述的过程就以一个因子扩大（扩展）这些单词边界框并记录那些交叉的边界框。 如果相应的单词在原始文档上彼此非常接近，则两个单词边界框将在扩展时交叉。 然后使用这样的规则将文本分组成区域：如果它们的单词边界框在扩张时交叉，则两个单词将属于相同的区域。 这样识别的文本区域被排序并返回。

    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN
    8.
    发明申请
    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
    包含PREGABALIN的持续释放药物组合物

    公开(公告)号：WO2012035559A3

    公开(公告)日：2012-06-28

    申请号：PCT/IN2011000638

    申请日：2011-09-15

    Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  SINGH SARABJIT ,  PUTHLI SHIVANAND

    Inventor： JAIN RAJESH ,  SINGH SARABJIT ,  PUTHLI SHIVANAND

    IPC: A01N37/12 ,  A61K31/195

    CPC classification number: A61K9/0002 ,  A61K9/1623 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/197 ,  A61K47/26

    Abstract: The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.

    Abstract translation: 本发明涉及稳定的每日缓释药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普瑞巴林的常规速释制剂每天施用两次是生物等效的。 本发明进一步涉及包含普瑞巴林和糖酯作为用于维持药物的均匀释放速率的释放延缓剂的组合物以及制备这种口服缓释制剂的方法。

Patent Agency Ranking